In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
PREGNANCY: A teratogen in animal studies. Drug usage in pregnant women should be conducted only after necessary studies and approvals from regulatory agencies.
Based on its teratogenic properties in developed chick embryos, it is recommended that rolapitant should be taken only when a valid diagnosis has been established and only at the recommended dose, not at a larger dose or for an extended period of time. Drug usage in pregnant women should be conducted after necessary studies and approvals from regulatory agencies.
(Cureus, 2022 Aug 17;14(8):e28097, doi: 10.7759/cureus.28097)
Please login to view the rest of this drug profile.